CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31, 2022 . “During the first quarter of 2022 we continued to see reductions in our
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2022-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2021 financial results for the period ended December 31, 2021 . “During 2021 we have continued to reduce our operating expenses and remain
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2021-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2021 financial results for the period ended September 30, 2021 . “Both Ipsen Pharmaceuticals and Elevation Oncology publicly announced
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2021-- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, 2021 . “We are pleased to report continued reductions in our operating expenses as
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 10, 2021-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2020 financial results for the period ended December 31, 2020 . “We are pleased that both Ipsen Pharmaceuticals and Elevation Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2020 financial results for the period ended September 30, 2020 . “We are pleased that both Ipsen Pharmaceuticals and Elevation Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its second quarter 2020 financial results for the period ended June 30, 2020 . “We are pleased by recent news releases from both Ipsen Pharmaceuticals and
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2020 financial results for the period ended March 31, 2020 . “We are pleased to report that we have significantly reduced our operating
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2019-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has adopted a Section 382 net operating loss rights plan (the “ Plan ”) and declared a dividend
